Oppenheimer reissued their hold rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a research report released on Monday.

Other equities research analysts have also issued research reports about the company. UBS Group reaffirmed a buy rating and issued a $50.00 price objective (up previously from $36.00) on shares of Acceleron Pharma in a report on Tuesday, September 12th. HC Wainwright started coverage on Acceleron Pharma in a report on Thursday, October 12th. They issued a buy rating and a $57.00 price objective on the stock. BidaskClub raised Acceleron Pharma from a hold rating to a buy rating in a report on Wednesday, December 27th. Credit Suisse Group set a $51.00 price objective on Acceleron Pharma and gave the company a buy rating in a report on Tuesday, November 14th. Finally, Royal Bank of Canada reaffirmed a hold rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company’s stock. Acceleron Pharma currently has an average rating of Buy and an average price target of $44.56.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded up $0.21 on Monday, reaching $44.01. The company’s stock had a trading volume of 274,800 shares, compared to its average volume of 329,686. Acceleron Pharma has a 12 month low of $23.07 and a 12 month high of $44.80. The stock has a market cap of $1,930.00, a price-to-earnings ratio of -17.06 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. During the same quarter in the previous year, the company earned ($0.55) EPS. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts anticipate that Acceleron Pharma will post -2.65 EPS for the current fiscal year.

In related news, EVP Matthew L. Sherman sold 4,633 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $42.71, for a total transaction of $197,875.43. Following the completion of the transaction, the executive vice president now directly owns 77,700 shares in the company, valued at approximately $3,318,567. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin F. Mclaughlin sold 19,000 shares of Acceleron Pharma stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $42.89, for a total value of $814,910.00. Following the transaction, the chief financial officer now owns 45,300 shares of the company’s stock, valued at $1,942,917. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 135,021 shares of company stock valued at $5,034,598. Insiders own 3.90% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP raised its position in shares of Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Acceleron Pharma by 969.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 3,288 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Acceleron Pharma during the 3rd quarter worth approximately $225,000. Trexquant Investment LP acquired a new position in shares of Acceleron Pharma during the 3rd quarter worth approximately $266,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Acceleron Pharma by 57.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 3,100 shares during the last quarter. Hedge funds and other institutional investors own 85.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Oppenheimer Reiterates “Hold” Rating for Acceleron Pharma (XLRN)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/11/oppenheimer-reiterates-hold-rating-for-acceleron-pharma-xlrn.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related stocks with our FREE daily email newsletter.